Erratum: Human Leukocyte Antigen E Contributes to Protect Tumor Cells from Lysis by Natural Killer Cells12 (Neoplasia (2011) 113(9) (822–830) (S1476558611800345) (10.1593/neo.101684));Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells

Neoplasia

Volumn 13, Issue 9, 2011, Pages 822-830

  lo Monaco, Elisa ^a   Tremante, Elisa ^a   Cerboni, Cristina ^b   Melucci, Elisa ^a   Sibilio, Leonardo ^a,d   Zingoni, Alessandra ^b   Nicotra, Maria Rita ^a   Natali, Pier Giorgio ^c   Giacomini, Patrizio ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d Istituto Biochimico Italiano (IBI) Lorenzini   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA E ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2A; PROTEIN DNAM1; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN STRUCTURE; ARTICLE; CELL LINEAGE; CELL PROTECTION; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LYMPHOID CELL; MALIGNANT TRANSFORMATION; NATURAL KILLER CELL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL; TUMOR CELL LINE;

EID: 80053444892     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/S1476-5586(11)80096-5     Document Type: Erratum

References (12)

1. Sarkar S, Glassy MC, Ferrone S, and Jones OW (1980). Cell cycle and the differential expression of HLA-A,B and HLA-DR antigens on human B lymphoid cells. Proc Natl Acad Sci USA 77, 7297-7301.
2. Hakem R, Le Bouteiller P, Barad M, Trujillo M, Mercier P, Wietzerbin J, and Lemonnier FA (1989). IFN-mediated differential regulation of the expression of HLA-B7 and HLA-A3 class I genes. J Immunol 142, 297-305.
3. 2-microglobulin. Hum Immunol 53, 23-33.
4. Martayan A, Fraioli R, Giorda E, Setini A, Ciccarelli G, Delfino L, Ferrara GB, and Giacomini P (1999). Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. Br J Cancer 80, 639-649.
5. Delfino L, Ciccarelli G, Bini D, Morabito A, Pozzi S, Martayan A, Giorda E, Setini A, Fraioli R, Giacomini P, et al. (1999). HLA-A, -B, -C genotyping and expression in human nonlymphoid tumor cell lines. J Immunother 22, 7-15.
6. Giacomini P, Giorda E, Fraioli R, Nicotra MR, Vitale N, Setini A, Delfino L, Morabito A, Benevolo M, Venturo I, et al. (1999). Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines. Cancer Res 59, 2657-2667.
7. Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB, and Pistillo MP (2005). HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol 66, 1-12.
8. Adams S, Robbins FM, Chen D, Wagage D, Holbeck SL, Morse HC, Stroncek D, and Marincola FM (2005). HLA class I and II genotype of the NCI-60 cell lines. J Transl Med 3, 1-11.
9. Lee N, Goodlett DR, Ishitani A, Marquardt H, and Geraghty DE (1998). HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 160, 4951-4960.
10. 2m and surface expression in the absence of HLA class I signal sequence-derived peptides. J Immunol 181, 5442-5450.
11. Marìn R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, and Garrido F (2003). Analysis of HLA-E expression in human tumors. Immunogenetics 54, 767-775.
12. Fruci D, Ferracuti S, Limongi MZ, Cunsolo V, Giorda E, Fraioli R, Sibilio L, Carroll O, Hattori A, van Endert PM, et al. (2006). Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/ lymphoma, carcinoma, and melanoma cell lines. J Immunol 176, 4869-4879.